Leustatin

Cladribine, the active ingredient in Leustatin, is a purine nucleoside analog presented as an intravenous solution for intravenous use. It is employed in the management of multiple sclerosis and hairy cell leukemia, targeting abnormal lymphocytes in adult patients.

GNH USA supplies Leustatin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with rigorous quality assurance and regulatory compliance. Our distribution network ensures timely delivery and supports import documentation for global markets, including cold‑chain logistics where required.

Leustatin (cladribine) is indicated for diseases involving abnormal lymphocyte activity.

- Multiple sclerosis (relapsing forms): reduces relapse frequency and MRI disease activity in adults. - Multiple sclerosis (active disease): slows progression and reduces disability accumulation. - Hairy cell leukemia: induces durable remission by depleting malignant B‑cells.

Cladribine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Lymphopenia: reduced lymphocyte counts. - Nausea: mild gastrointestinal upset. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Severe lymphopenia with opportunistic infections. - Autoimmune hepatitis or severe liver injury. - Serious skin reactions such as Stevens‑Johnson syndrome.

Before and during treatment with cladribine, several safety measures should be observed.

- Monitor blood counts: perform regular CBC to detect lymphopenia. - Assess infection risk: screen for active infections before initiating therapy. - Avoid live vaccines: live attenuated vaccines may cause disease during immunosuppression. - Adjust for renal impairment: dose may need modification in patients with reduced renal function. - Contraindicated in severe immunodeficiency: do not use in patients with uncontrolled HIV or active malignancies other than the target disease. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other myelosuppressive chemotherapy agents: may cause profound bone marrow suppression. - Live vaccines: increased risk of vaccine‑derived infection. - Strong immunosuppressive biologics: additive immunosuppression may lead to severe infections.

Moderate Interactions (Monitor Closely): - Antiviral prophylaxis agents: monitor for potential dose adjustments. - Non‑live vaccines: immune response may be attenuated, requiring efficacy assessment. - Renally cleared drugs: monitor renal function to avoid accumulation.